IDH1 and neoplasm: These results have paved the way for continued clinical trials of these inhibitors either alone or in combination.7,8,41,42 But enhanced patient survival following mutant IDH inhibitor treatment has been associated, most commonly, with inhibition in tumor growth particularly when tumor growth is measured volumetrically.43 As a result, complementary metabolic imaging methods that can help confirm drug target engagement are essential.